Audio Interview

SARS-COV-2 human monoclonal antibody therapy update

Published on June 10, 2021   11 min

Other Talks in the Playlist: Interviews on Covid-19

Please wait while the transcript is being prepared...
Interviewer: Professor Crowe, thank you for doing this interview with us today to update us on the work being done by you and your team, on SARS-CoV-2 human monoclonal antibodies for the COVID-19 pandemic. Could you please give an overview on how the work in your lab has developed since your last interview with us in May 2020? Prof. Crowe: Yes, thanks for having me back, its been a year, it's interesting to look back and see where we were then and where we are now. In May 2020, we were just completing a massive series of what we call 'sprint' antibody discoveries, where we worked as hard as possible, our people were up here 20 hours a day, some of them didn't take a day off for months until May. We discovered thousands of antibodies, and down-selected to a panel of a dozen or so. We partnered with various companies and groups to put those into clinical trials. Now a year later, we're seeing the completion of much of that original work. Right now, I think there are six phase III efficacy trials with our partner AstraZeneca. There's prevention, post-exposure prophylaxis, mild-to-moderate disease, and then hospitalized disease and so on. Some of those trials are fully enrolled and we'll hear the answer. We've been supporting those clinical trial programs with AstraZeneca and also IDBiologics, and then the United States government through JPO and their contractor Ology is doing trials in the Department of Defense. Lots of clinical trials going on and we have high expectations that these will be beneficial, but now we're turning to things like variants.

SARS-COV-2 human monoclonal antibody therapy update

Embed in course/own notes